Новые схемы и новые препараты в лечении туберкулеза: шагаем в ногу? | КМАХ

Новые схемы и новые препараты в лечении туберкулеза: шагаем в ногу?

Клиническая микробиология и антимикробная химиотерапия. 2021; 23(1):27-42

​ Рузанов Д.Ю., Скрягина Е.М., Буйневич И.В., Гопоняко С.В., Баласанянц Г.С., Химова Е.С.
10.36488/cmac.2021.1.27-42
туберкулез лекарственная устойчивость схемы лечения бедаквилин деламанид
Раздел
Болезни и возбудители
Тип
Обзор
Публикация
Клиническая микробиология и антимикробная химиотерапия. 2021; 23(1):27-42

Аннотация

Появление и повсеместное внедрение в практику ускоренных методов детекции и тестирования лекарственной устойчивости микобактерий туберкулеза привели к резкому уменьшению сроков постановки диагноза рифампициноустойчивого туберкулеза и возможности раннего назначения этиотропного лечения. Но постоянно растущая устойчивость микобактерий к противотуберкулезным препаратам снижает эффективность лечения. Кроме того, применяемые схемы лечения лекарственно-устойчивого туберкулеза из-за низкой стерилизующей активности требуют длительного использования, что ведет к повышению токсичности препаратов, снижению приверженности лечению пациентов, значительному увеличению ресурсов здравоохранения. Современная фтизиатрия нуждается в разработке новых эффективных лекарственных средств и коротких схем лечения, без чего невозможна элиминация туберкулеза к 2050 г. В данном обзоре авторы обобщили информацию о лечении лекарственно-устойчивого туберкулеза, в том числе сведения о перепрофилированных лекарствах, новых препаратах и схемах лечения.

Рузанов Дмитрий Юрьевич

Республиканский научно-практический центр медицинских технологий, информатизации, управления и экономики здравоохранения, Минск, Республика Беларусь

Скрягина Е.М.

Республиканский научно-практический центр пульмонологии и фтизиатрии, Минск, Республика Беларусь

Буйневич И.В.

УО «Гомельский государственный медицинский университет», Гомель, Республика Беларусь

Гопоняко С.В.

УО «Гомельский государственный медицинский университет», Гомель, Республика Беларусь

Баласанянц Г.С.

ФГБВОУ ВО «Военно-медицинская академия им. С.М. Кирова» Минобороны России, Санкт-Петербург, Россия

Химова Е.С.

ФГБОУ ВО «Северный государственный медицинский университет» Минздрава России, Архангельск, Россия

  • 1. World Health Organization. Global tuberculosis report 2019 (WHO/CDS/TB/2019.15). 2020. Available at: www.who.int/tb/publications/global_report/en/. Accessed January 30, 2021.
  • 2. World Health Organization. Guidelines for the management of drug-resistant tuberculosis (WHO/TB/96.210 Rev.1). 1997. Available at: https://apps.who.int/iris/bitstream/handle/106665/63465/WHO_TB_96.210_(Rev.1).pdf;jsessionid=20AD8869DC687E069E0D25D8267E4025?sequence=1. Accessed January 30, 2021.
  • 3. Hughes J., Isaakidis P., Andries A., Mansoor H., Cox V., Meintjes G., et al. Linezolid for multidrugresistant tuberculosis in HIV-infected and -uninfected patients. Eur Respir J. 2015;46:271-274. DOI: 10.1183/09031936.00188114
  • 4. Lienhardt C., Raviglione M., Spigelman M., Hafner R., Jaramillo E., Hoelscher M., et al. New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future. J Infect Dis. 2012;205:241-249. DOI: 10.1093/infdis/jis034
  • 5. Tiberi S., Payen M.C., Sotgiu G., D’Ambrosio L., Alarcon Guizado V., Alffenaar J.W., et al. Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB. Eur Respir J. 2016;47:12351243. DOI: 10.1183/13993003.02146-2015
  • 6. Skripconoka V., Danilovits M., Pehme L., Tomson T., Skenders G., Kummik T., et al. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J. 2013;41:1393-1400. DOI: 10.1183/09031936.00125812
  • 7. Wallis R.S., Maeurer M., Mwaba P., Chakaya J., Rustomjee R., Migliori G.B. Tuberculosis – advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers. Lancet Infect Dis. 2016;16:3446. DOI: 10.1016/S1473-3099(16)00070-0
  • 8. Tiberi S., Muñoz-TorricoM., Duarte R., Dalcolmo M., D’Ambrosio L., Migliori, G-B. New drugs and perspectives for new anti-tuberculosis regimens. Pulmonology. 2018;24(2):86-98. DOI: 10.1016/j.rppnen.2017.10.009
  • 9. Falzon D., Gandhi N., Migliori G.B., Sotgiu G., Cox H.S., Holtz T.H., et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J. 2013;42:156-168. DOI: 10.1183/09031936.00134712
  • 10. Guglielmetti L., Le Dû D., Veziris N., Caumes E., MarigotOuttandy D., Yazdanpanah Y., et al. Is bedaquiline as effective as fluoroquinolones in the treatment of multidrugresistant tuberculosis? Eur Respir J. 2016;48:582-585. DOI: 10.1183/13993003.00411-2016
  • 11. Gillespie S.H., Crook A.M., McHugh T.D., Mendel C.M., Meredith S.K., Murray S.R., et al. Four month moxifloxacinbased regimens for drug-sensitive tuberculosis. N Engl J Med. 2014;371:1577-1587. DOI: 10.1056/NEJMoa1407426
  • 12. Merle C.S., Fielding K., Sow O.B., Gninafon M., Lo M.B., Mthiyane T., et al. A four-month gatifloxacincontaining regimen for treating tuberculosis. N Engl J Med. 2014;371:1588-1598. DOI: 10.1056/NEJMoa1315817
  • 13. Jawahar M.S., Banurekha V.V., Paramasivan C.N., Rahman F., Ramachandran R., Venkatesan P., et al. Randomized clinical trial of thrice weekly 4-month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients. PLoS One. 2013;8(7):e67030. DOI: 10.1371/journal.pone.0067030
  • 14. Blasi F., Dara M., van der Werf M.J., Migliori G.B. Supporting TB clinicians managing difficult cases: the ERS/WHO consilium. Eur Respir J. 2013;41:491-494. DOI: 10.1183/09031936.00196712
  • 15. Horsburgh Jr. C.R., Barry C.E. 3rd, Lange C. Treatment of tuberculosis. N Engl J Med. 2015;373:2149-2160. DOI: 10.1056/NEJMra 1413919
  • 16. Ashtekar D.R., Costa-Periera R., Shrinivasan T., Iyyer R., Vishvanathan N., Rittel W. Oxazolidinone, a new class of synthetic antituberculosis agent: in vitro and in vivo activities of DuP-721 against Mycobacterium tuberculosis. Diagn Microbiol Infect Dis. 1991;14:465-471. DOI: 10.1016/0732-8893(91)90002-w
  • 17. Sotgiu G., Centis R., D’Ambrosio L., Alffenaar J.W., Anger H.A., Caminero J.A., et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and metaanalysis. Eur Respir J. 2012;40:1430-1442. DOI: 10.1183/09031936.00022912
  • 18. Sotgiu G., Pontali E., Migliori G.B. Linezolid to treat MDR-/XDR-tuberculosis: available evidence and future scenarios. Eur Respir J. 2015;45:25-29. DOI: 10.1183/09031936.00145014
  • 19. Sotgiu G., Tiberi S., D’Ambrosio L., Centis R., Alffenaar J.W., Caminero J.A. Faster for less: the new “shorter” regimen for multidrug-resistant tuberculosis. Eur Respir J. 2016;48:15031507. DOI: 10.1183/13993003.01249-2016
  • 20. Van Deun A., Salim M.A., Das A.P., Bastian I., Portaels F. Results of a standardised regimen for multidrug-resistant tuberculosis in Bangladesh. Int J Tuberc Lung Dis. 2004;8:560-567. PMID: 15137531.
  • 21. Tang S., Yao L., Hao X., Liu Y., Zeng L., Liu G., et al. Clofazimine for the treatment of multidrug-resistant tuberculosis: prospective, multicenter, randomized controlled study in China. Clin Infect Dis. 2015;60:13611367. DOI: 10.1093/cid/civ027
  • 22. Tiberi S., D’Ambrosio L., De Lorenzo S., Viggiani P., Centis R., Sotgiu G., et al. Ertapenem in the treatment of multidrugresistant tuberculosis: first clinical experience. Eur Respir J. 2016;47:333-336. DOI: 10.1183/13993003.012782015
  • 23. Diacon A.H., van der Merwe L., Barnard M., von GrooteBidlingmaier F., Lange C., García-Basteiro A.L., et al. b-Lactams against tuberculosis – new trick for an old dog? N Engl J Med. 2016;375:393-394. DOI: 10.1056/NEJMc1513236
  • 24. Anglaret X., Chêne G., Attia A., Toure S., Lafont S., Combe P., et al. Early chemoprophylaxis with trimethoprimsulphamethoxazole for HIV-1-infected adults in Abidjan, Côte d’Ivoire: a randomised trial. Lancet. 1999;353:14631468. DOI: 10.1016/s0140-6736(98)07399-1
  • 25. Walker A.S., Ford D., Gilks C.F., Munderi P., Ssali F., Reid A., et al. Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort. Lancet. 2010;375:1278-1286. DOI: 10.1016/S0140-6736(10)60057-8
  • 26. Krieger D., Vesenbeckh S., Schönfeld N., Bettermann G., Bauer T.T., Russmann H., et al. Mefloquine as a potential drug against multidrug-resistant tuberculosis. Eur Respir J. 2015;46:1503-1505. DOI: 10.1183/13993003.003212015
  • 27. Van der Paardt A.L., Akkerman O.W., Gualano G., Palmieri F., Davies Forsman L., Aleksa A., et al. Safety and tolerability of clarithromycin in the treatment of multidrugresistant tuberculosis. Eur Respir J. 2017;49:1601612. DOI: 10.1183/13993003.01612-2016
  • 28. Working Group on New TB Drugs. Available at: www.newtbdrugs.org/pipeline/clinical. Accessed June 27, 2020.
  • 29. NIH. U.S. National Library of Medicine. Available at: https://clinicaltrials.gov/ct2/show/NCT01225640. Accessed June 16, 2020.
  • 30. World Health Organization. Technical report on critical concentrations for TB drug susceptibility testing of medicines used in the treatment of drug-resistant TB. 2018. Available at: www.who.int/tb/publications/2018/. Accessed January 2021.
  • 31. Policy brief 29 World Health Organization 2018. Ensuring access to medicines: How to stimulate innovation to meet patients’ needs? Addressing policy failures in pharmaceuticals series editor. 2018. Available at: www. euro.who.int/data/assets/pdf_file/0009/379701/PB29. Accessed January 2021.
  • 32. Sirturo (bedaquiline) [website]. Amsterdam, The Netherlands European Medicines Agency; 2020. Available at: www.ema.europa.eu/en/medicines/human/EPAR/sirturo. Accessed March 20, 2020.
  • 33. Maryland, United States of America: US Food and Drug Administration. Sirturo (bedaquiline 100 mg tablets) For the treatment of adults (≥ 18 years) as part of combination therapy of pulmonary multi-drug resistant tuberculosis (MDRTB). November 28, 2012. Available at: www.natap.org/2013/newsUpdates/20121128-AIDAC-B1–01FDA_Backgrounder.pdf. Accessed March 20, 2020.
  • 34. World Health Organization. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis. Interim policy guidance (WHO/HTM/TB/2013.6). 2013. Available at: http://apps.who.int/iris/bitstream/handle/10665/84879/9789241505482_eng.pdf?sequence=1. Accessed January 2021.
  • 35. World Health Organization. The use of delamanid in the treatment of multidrug-resistant tuberculosis. Interim policy guidance (WHO/HTM/TB/2014.23). 2014. Available at: http://apps.who.int/iris/bitstream/handle/10665/137334/WHO_HTM_TB_2014.23_eng.pdf?sequence=1. Accessed March 20, 2020.
  • 36. European Medicines Agency. Deltyba. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/deltyba. Accessed March 20, 2020.
  • 37. Sasaki H., Haraguchi Y., Itotani M., Kuroda H., Hashizume H., Tomishige T., et al. Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles. J Med Chem. 2006;49:7854-7860. DOI: 10.1021/jm060957y
  • 38. Tsubouchi H., Sasaki H., Ishikawa H., Matsumoto M. Discovery of delamanid for the treatment of multidrugresistant pulmonary tuberculosis. In: Successful Drug Discovery (eds J. Fischer and W.E. Childers); 2016. Charter 7. DOI: 10.1002/9783527800315.ch7
  • 39. Liu Y., Matsumoto M., Ishida H., Ohguro K., Yoshitake M., Gupta R., et al. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB). Тuberculosis. 2018;111:20-30. DOI: 10.1016/j.tube.2018.04.008
  • 40. Upton A.M., Cho S., Yang T.J., Kim A.Y., Wang Y., Lu Y., et al. In vitro and in vivo activities of the nitroimidazole TBA-354 against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2015;59:136-144. DOI: 10.1128/AAC.03823-14
  • 41. Matsumoto M., Hashizume H., Tomishige T., Kawasaki M., Tsubouchi H., Sasaki H., et al. OPC-67683, a nitro-dihydroimidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med. 2006;3:21312144. DOI: 10.1371/journal.pmed.0030466
  • 42. Chen X., Hashizume H., Tomishige T., Nakamura I., Matsuba M., Fujiwara M., et al. Delamanid kills dormant mycobacteria in vitro and in a Guinea pig model of tuberculosis. Antimicrob Agents Chemother. 2017;61:111. DOI: 10.1128/AAC.02402-16
  • 43. Doi N., Disratthakit A. Characteristic antimycobacterial spectra of the novel anti-TB drug candidates OPC-67683 and PA-824. Presented at Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, CA, 2016. Poster F1-1377a.
  • 44. Shimokawa Y., Sasahara K., Koyama N., Kitano K., Shibata M., Yoda N., et al. Metabolic mechanism of delamanid, a new anti-tuberculosis drug, in human plasma. Drug Metab Dispos. 2015;43:1277-1283. DOI: 10.1124/dmd.115.064550
  • 45. Gupta R., Geiter L.J., Hafkin J., Wells C.D. Delamanid and QT prolongation in the treatment of multidrug-resistant tuberculosis. Int J Tubercul Lung Dis. 2015;19:1261-1262. DOI: 10.5588/ijtld.15.0541
  • 46. Fujiwara M., Kawasaki M., Hariguchi N., Liu Y., Matsumoto M. Mechanisms of resistance to delamanid, a drug for mycobacterium tuberculosis. Tuberculosis. 2018;108:186-194. DOI: 10.1016/j.tube.2017.12.006
  • 47. Mallikaarjun S., Wells C., Petersen C., Paccaly A., Shoaf S.E., Patil S., et al. Delamanid coadministered with antiretroviral drugs or antituberculosis drugs shows no clinically relevant drug-drug interactions in healthy subjects. Antimicrob Agents Chemother. 2016;60:5976-5985. DOI: 10.1128/AAC.00509-16
  • 48. World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis, 2016 update (WHO/HTM/TB/2016.4). 2016. Available at: www.who.int/publications/i/item/9789241549639. Accessed January 30, 2021.
  • 49. Sotgiu G., Tiberi S., D’Ambrosio L., Centis R., Zumla A., Migliori G.B. WHO recommendations on shorter treatment of multidrug-resistant tuberculosis. Lancet. 2016;387:24862487. DOI: 10.1016/S0140-6736(16)30729-2
  • 50. World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment, (WHO/CDS/TB/2019.7). 2019. Available at: https://apps.who.int/iris/bitstream/handle/10665/311389/9789241550529eng.pdf?ua=1. Accessed January 30, 2021.
  • 51. World Health Organization. WHO Consolidated Guidelines on Tuberculosis. Module 4: treatment – drug-resistant tuberculosis treatment. 2020. Available at: https://apps.who.int/iris/bitstream/handle/10665/329298/9789289054461-rus.pdf?sequence=1&isAllowed=y. Accessed January 30, 2021. Russian. (Всемирная организация здравоохранения. Сводное руководство ВОЗ по туберкулезу. Модуль 4: лечение лекарственно-устойчивого туберкулеза. 2020. Доступно по адресу: https://apps.who.int/iris/bitstream/handle/10665/329298/9789289054461rus.pdf?sequence=1&isAllowed=y. Ссылка активна на 30 января 2021 г.)
  • 52. Borisov S.E., Dheda K., Enwerem M., Romero Leyet R., D’Ambrosio L., Centis R., et al. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study. Eur Respir J. 2017;49(5):1700387. DOI: 10.1183/13993003.00387-2017
  • 53. Hafkin J., Hittel N., Martin A., Gupta R. Early outcomes in MDR-TB and XDR-TB patients treated with delamanid under compassionate use. Eur Respir J. 2017;50:1700311. DOI: 10.1183/13993003.00311-2017
  • 54. Von Groote-Bidlingmaier F., Patientia R., Sanchez E., Balanag V. Jr, Ticona E., Seguraet P., et al. Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial. Lancet. Respir Med. 2019;7(3):249-259. DOI: 10.1016/s22132600(18)30426-0
  • 55. Lorsanov S.M., Khaydarkhanova Z.B., Khunkarsultanov S.B. The experience of using delamanid in the Chechen Republic. Tuberkuljoz i bolezni ljogkih. 2019;97(12):6263. Russian. (Лорсанов С.М., Хайдарханова З.Б., Хункарсултанов С.Б. Опыт применения деламанида в Чеченской Республике. Туберкулёз и болезни лёгких. 2019;97(12):62-63.) DOI: 10.21292/2075-12302019-97-12-62-63
  • 56. World Health Organization. Global tuberculosis report 2016. Available at: https://apps.who.int/iris/handle/10665/250441. Accessed January 30, 2021.
  • 57. Sotgiu G., Tiberi S., D’Ambrosio L., Centis R., Alffenaar J.W., Caminero J.A. Faster for less: the new ‘shorter’ regimen for multidrug-resistant tuberculosis. Eur Respir J. 2016;48:15031507. DOI: 10.1183/13993003.01249-2016
  • 58. Van Deun A., Maug A., Salim A., Das P., Sarker M., Daru P., et al. Short, highly effective, and inexpensive standardised, treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2010;182:684-692. DOI: 10.1164/rccm.201001-0077OC
  • 59. Aung K.J., Van Deun A., Declercq E., Sarker M.R., Das P.K., Hossain M.A., et al. Successful ‘9-month Bangladesh regimen’ for multidrugresistant tuberculosis among over 500 consecutive patients. Int J Tuberc Lung Dis. 2014:18:11801187. DOI: 10.5588/ijtld.14.0100
  • 60. Ahmad Khan F., Salim M.A.H., du Cros P., Casas E.C., Khamraev A., Sikhondze W., et al. Effectiveness and safety of standardised shorter regimens for multidrug-resistant tuberculosis: individual patient data and aggregate data meta-analyses. Eur Respir J. 2017;50:1700061. DOI: 10.1183/13993003.00061-2017
  • 61. Combs D.L., O’Brien R.J., Geiter L.J. USPHS Tuberculosis Short-Course Chemotherapy Trial: effectiveness, toxicity, and acceptability. The report of final results. Ann Intern Med. 1990;112(6):397-406. DOI: 10.7326/00034819-76-3-112-6-397
  • 62. World Health Organization. Guidelines for treatment of drug-susceptible tuberculosis and patient care 2017, update, (WHO/HTM/TB/2017.05). 2017. Available at: http://apps.who.int/iris/bitstream/handle/10665/255052/9789241550000-eng.pdf?sequence=1. Accessed January 30, 2021.
  • 63. World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: treatment – drug-resistant tuberculosis treatment. 2020. Available at: https://apps.who.int/iris/bitstream/handle/10665/332397/9789240007048eng.pdf?sequence=1&isAllowed=y. Accessed January 30, 2021.
  • 64. The Evaluation of a Standard Treatment Regimen of Antituberculosis Drugs for Patients With MDR-TB (STREAM). Available at: https://clinicaltrials.gov/ct2/show/NCT02409290. Accessed January 30, 2021.
  • 65. Moodley R., Godec T.R., STREAM Trial Team. Shortcourse treatment for multidrug-resistant tuberculosis: the STREAM trials. Eur Respir Rev. 2016;25(139):29-35. DOI: 10.1183/16000617.0080-2015
  • 66. Conradie F., Diacon A.H., Ngubane N. Treatment of highly drug-resistant pulmonary tuberculosis. N Engl J Med. 2020;382(10):893-902. DOI: 10.1056/NEJMoa1901814
  • 67. Mok J., Kang H., Hwang S.H., Park J.S., Kang B., Lee T., et al. Interim outcomes of delamanid for the treatment of MDR- and XDR-TB in South Korea. J Antimicrob Chemother. 2018;73(2):503-508. DOI: 10.1093/jac/dkx373
  • 68. Wirth D., Dass R., Hettle R. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany. BMC Health Serv Res. 2017;17(1):182. DOI: 10.1186/s12913-017-2118-2
  • 69. Colvin C., De Silva G., Garfin C., Alva S., Cloutier S., Gavoiola D., et al. Quality of TB services assessment: The unique contribution of patient and provider perspectives in identifying and addressing gaps in the quality of TB services. J Clin Tuberc Other Mycobact Dis. 2019;:100117. DOI: 10.1016/J.JCTUBE.2019.100117
  • 70. Khan U., Huerga H., Khan A.J., Mitnick C.D., Hewison C., Varaine F., et al. The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens. BMC Infect Dis. 2019;19(733). DOI: 10.1186/s12879-019-4378-4
  • 71. World Health Organization. WHO best-practice statement on the off-label use of bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis (WHO/HTM/TB/2017.20). 2017. Available at: https://apps.who.int/iris/bitstream/handle/10665/258941/WHO-HTM-TB2017.20-eng.pdf?sequence=1. Accessed January 30, 2021.
  • 72. Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q) (endTB-Q). ClinicalTrials.gov Identifier: NCT03896685. Available at: https://clinicaltrials.gov/ct2/show/NCT03896685. Accessed January 30, 2021.
  • 73. Skryagina A.M., Solodovnikova V.V., Klimuk D.A., Vetushko D.A., Yakubenya O.N, Zhurkin D.A. Preliminary treatment results of patients with XDR- and preXDR-TB using new anti-tuberculosis drugs. Achievements of medical science in Belarus. 2019. Heading 76.29.53. Russian. (Cкрягина Е.М., Солодовникова В.В., Климук Д.А., Ветушко Д.А., Якубеня О.Н., Журкин Д.А. Предварительные результаты лечения пациентов с ШЛУ- и преШЛУ-ТБ с использованием новых противотуберкулезных лекарственных средств. Достижения медицинской науки Беларуси. 2019. Рубрика 76.29.53.)
  • 74. World Health Organization. The use of delamanid in the treatment of multidrug-resistant tuberculosis in children and adolescents: Interim policy guidance. 2016. Available at: https://apps.who.int/iris/bitstream/handle/10665/250614/9789241549899-eng.pdf?sequence=1. Accessed January 30, 2021.
  • 75. Call to action: Accelerate access to DR-TB drugs. Available at: http://www.tbonline.info/posts/2015/3/17/callaction-accelerate-access-dr-tb-drugs-1. Accessed January 30, 2021.
  • 76. DR-TB Scale-up Treatment Action Team (STAT). Available at: http://drtb-stat.org/wp-content/uploads/2015/10/TermsofReference.pdf. Accessed January 30, 2021.
  • 77. Cumulative programmatic use of bedaquiline and delamanid. Available at: http://drtb-stat.org/wp-content/uploads/2020/04/DR-TB-STAT-March-2020-GlobalSummary.pdf. Accessed January 30, 2021.
  • 78. Wolfson L.J., Walker A., Hettle R., Lu X., Kambili C., Murungi A., Knerer G. Cost-effectiveness of adding bedaquiline to drug regimens for the treatment of multidrug-resistant tuberculosis in the UK. PLoS One. 2015;10(3):e0120763. DOI: 10.1371/journal.pone.0120763
  • 79. Veziris N., Bernard C., Guglielmetti L., Le Du D., MarigotOuttandy D., Jaspard M., et al. Rapid emergence of Mycobacterium tuberculosis bedaquiline resistance: lessons not to repeat past errors. Eur Respir J. 2017;49(3):1601719. DOI: 10.1183 / 13993003.01719-2016
  • 80. World Health Organization. Guidelines for establishing DOTS-Plus pilot projects for the management of multidrug-resistant tuberculosis (MDR-TB) (WHO/CDS/TB/2000.279). 2000. Available at: https://apps.who.int/iris/bitstream/handle/10665/66368/WHO_CDS_TB_2000.279.pdf?sequence=1. Accessed January 30, 2021.
  • 81. Conradie F., Diacon A.H., Ngubane N. Treatment of highly drug-resistant pulmonary tuberculosis. N Engl J Med. 2020;382(10):893-902. DOI: 10.1056/NEJMoa1901814
  • 82. World Health Organization. Rapid communication: key changes to treatment of multidrug-and rifampicinresistant tuberculosis (WHO/CDS/TB/2018.18). 2018. Available at: www.who.int/tb/publications/2018/rapid_communications_MDR/en/. Accessed October 12, 2020.
  • 83. Migliori G.B., Global Tuberculosis Network (GTN). Evolution of programmatic definitions used in tuberculosis prevention and care. Clin Infect Dis. 2019;68(10):17871789. DOI: 10.1093/cid/ciy990
  • 84. Centis R., Sotgiu G., Migliori G.B. Delamanid: does it have a role in tuberculosis treatment? Lancet Respir Med. 2019;7(3):193-195. DOI: 10.1016/s22132600(18)30455-7
  • 85. Clinical guidelines for the diagnosis and treatment of tuberculosis and its drug-resistant forms. Order of the ministry of health of the Republic of Belarus. Available at: www.rnpcpf.by/ru/organizacionno-metodicheskayarabota/normativno-pravovye-akty-po-slujbe.html?start=10. Russian. (Клиническое руководство по диагностике и лечению туберкулеза и его лекарственно-устойчивых форм (Приказ МЗ РБ от 30.05.2017 г. № 601). )
  • 86. Tuberculosis in adults. Clinical guidelines. 2020. Available at: https://legalacts.ru/doc/klinicheskie-rekomendatsiituberkulez-u-vzroslykh-utv-minzdravom-rossii/. Accessed January 30, 2021. Russian. (Туберкулез у взрослых. Клинические рекомендации. 2020. Доступно по адресу: https://legalacts.ru/doc/klinicheskie-rekomendatsiituberkulez-u-vzroslykh-utv-minzdravom-rossii/. Ссылка активна на 30 января 2021 г.).
  • 87. The list of vital and essential medicines for medical use in the Russian Federation for 2020. Approved by the order of the Government of the Russian Federation October 12, 2019 No 2406-p. Available at: http://government.ru/docs/38100. Accessed January 30, 2021. Russian. (Перечень жизненно необходимых и важнейших лекарственных препаратов для медицинского применения в РФ на 2020 год. Утвержден распоряжением Правительства Российской Федерации от 12 октября 2019 г. N 2406-р. Доступно по адресу: http://government.ru/docs/38100. Ссылка активна на 30 января 2021 г.).
  • 88. World Health Organization. Global tuberculosis report 2019 (WHO/CDS/TB/2019.15). 2020 Available at: https://www.who.int/tb/publications/global_report/en/. Accessed May 29, 2020.
  • 89. Hewison C., Ferlazzo G., Avaliani Z., Hayrapetyan A., Jonckheere S., Khaidarkhanova Z., et al. Six-month response to delamanid treatment in MDR TB patients. Emerg Infect Dis. 2017;23(10):1746-1748. DOI: 10.3201/eid2310.170468
  • 90. Kuksa L., Barkane L., Hittel N., Gupta R. Final treatment outcomes of multidrug- and extensively drug-resistant tuberculosis patients in Latvia receiving delamanidcontaining regimens. Eur Respir J. 2017;50:2-5. DOI: 10.1183/13993003.01105-2017
Просмотров
0 Аннотация
0 PDF
0 Цитирования
Поделились